Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vertex CF Combo Succeeds In Phase III, But Secondary Endpoints May Be Crucial

This article was originally published in The Pink Sheet Daily

Executive Summary

Vertex’s two-drug combo for cystic fibrosis hits primary and several key secondary endpoints in a pair of pivotal trials, although data from the primary endpoint underwhelms some observers. Strong data from a pair of secondary endpoints, however, may provide real-world strategic value for the combo.


Related Content

Vertex Phase III For CF Combo Shows Power Of “Breakthrough” Designation


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts